[A case of intestinal Behçet's disease with abnormal ossification complicated by myelodysplastic syndrome, symptoms revealed after the perforation of ileum ulcer].
A 39-year-old man, who had been treated with Etretinate for common wart since he was 29 years old, was admitted to Taga General Hospital complaining of gradually deteriorating lumbago and bilateral hip joints pain in September, 1996. His lower vertebrae and bilateral hip joints showed abnormal ossification on X-ray. The bone scintigraphy indicated the existence of sacroiliitis. His platelet counts were fluctuating between 8 x 10(4) and 9 x 10(4)/mm3. During the follow-up in our out-patient clinic, he was suddenly suffered from severe abdominal pain in August, 1997 and admitted to our hospital. An emergency operation revealed multiple ulcers of his ileum with several perforations. Histological findings of the specimen of the ileum showed simple ulcer. After the operation, he had oral and genital ulcers. He did not have any signs or symptoms of ocular involvement. He was diagnosed as intestinal Behçet's disease. Because he showed gradually pancytopenia for several months after the operation, bone marrow aspiration was performed and a diagnosis of refractory anemia, a type of myelodysplastic syndrome (MDS), with trisomy of chromosome 8 was made. Abnormal ossification of his vertebrae and hip joints were considered to be related to Behçet's disease because an coexistence with sacroiliitis. On the other hand, there is no denying the effects of orally Etretinate administration. Several cases have been reported the association of MDS with Behçet's disease. In this case, the existence of MDS or various symptoms in Behçet's disease became apparent after the perforation of ileum ulcer. This paper discusses possible etiology of the relation between Behçet's disease and MDS, or the characteristic clinical course in this case.
Tanaka
E
E
Department of Rheumatology, Taga General Hospital, Ibaraki.
Nishinarita
M
M
Uesato
M
M
Kamatani
N
N
D000328:Adult; D001528:Behcet Syndrome / Q000150:complications*; D005050:Etretinate / Q000009:adverse effects; D006801:Humans; D007077:Ileal Diseases / Q000150:complications*; D007410:Intestinal Diseases / Q000150:complications*; D007416:Intestinal Perforation / Q000209:etiology*; D007641:Keratolytic Agents / Q000009:adverse effects; D008297:Male; D009190:Myelodysplastic Syndromes / Q000150:complications*; D009999:Ossification, Heterotopic / Q000150:complications*; D014456:Ulcer / Q000150:complications*
D007641:Keratolytic Agents; D005050:Etretinate